Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials DOI Creative Commons
Zixin Cai, Jiaxin Zhong, Guanghui Zhu

и другие.

The Journal of Prevention of Alzheimer s Disease, Год журнала: 2025, Номер unknown, С. 100111 - 100111

Опубликована: Фев. 1, 2025

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options. Emerging evidence suggests that antidiabetic agents may offer neuroprotective effects by targeting shared pathophysiological mechanisms such as insulin resistance and neuroinflammation. However, the comparative efficacy, safety of these in AD remain unclear. This study aimed to systematically evaluate compare efficacy for improving cognitive outcomes, reducing amyloid-β (Aβ) deposition, managing adverse patients AD, using network meta-analysis randomized controlled trials (RCTs). A comprehensive literature search was conducted across multiple databases identify RCTs examining AD. The primary outcomes included performance (e.g., MMSE scores), Aβ deposition (measured via CSF biomarkers), safety/adverse effects. performed integrate direct indirect evidence, ranking interventions Surface Under Cumulative Ranking (SUCRA) probabilities. Risk bias assessed Cochrane risk-of-bias tool. total 26 studies, involving 7,361 participants, were analysis. evaluated detemir (both low-dose high-dose), liraglutide, exenatide, metformin, pioglitazone. Both (mean difference: 2.10, 95 % CI: 1.04 3.15), high-dose 1.40, -0.07 2.88), exenatide 1.19, 0.06 2.32), metformin combined 1.06, -1.68 3.80) showed improvements compared placebo. Among these, demonstrated most significant improvement. In terms ranked highest effectiveness, SUCRA score (84.6), followed (SUCRA: 54.1). Low-dose 51.1) also moderate efficacy. some reduction -0.31, -2.82 2.20), although statistical significance limited. Liraglutide exhibited rate withdrawal 1.97, 4.00), while pioglitazone lowest rates 0.07, -0.03 0.17). provides valuable insights into improvement effect on deposition. Metformin emerged effective agent levels, though its function less pronounced. Safety profiles varied, liraglutide associated withdrawals, incidence treatment-related discontinuations. These findings support potential use agents, particularly detemir, therapeutic option further studies are needed confirm their long-term benefits safety.

Язык: Английский

Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials DOI Creative Commons
Zixin Cai, Jiaxin Zhong, Guanghui Zhu

и другие.

The Journal of Prevention of Alzheimer s Disease, Год журнала: 2025, Номер unknown, С. 100111 - 100111

Опубликована: Фев. 1, 2025

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options. Emerging evidence suggests that antidiabetic agents may offer neuroprotective effects by targeting shared pathophysiological mechanisms such as insulin resistance and neuroinflammation. However, the comparative efficacy, safety of these in AD remain unclear. This study aimed to systematically evaluate compare efficacy for improving cognitive outcomes, reducing amyloid-β (Aβ) deposition, managing adverse patients AD, using network meta-analysis randomized controlled trials (RCTs). A comprehensive literature search was conducted across multiple databases identify RCTs examining AD. The primary outcomes included performance (e.g., MMSE scores), Aβ deposition (measured via CSF biomarkers), safety/adverse effects. performed integrate direct indirect evidence, ranking interventions Surface Under Cumulative Ranking (SUCRA) probabilities. Risk bias assessed Cochrane risk-of-bias tool. total 26 studies, involving 7,361 participants, were analysis. evaluated detemir (both low-dose high-dose), liraglutide, exenatide, metformin, pioglitazone. Both (mean difference: 2.10, 95 % CI: 1.04 3.15), high-dose 1.40, -0.07 2.88), exenatide 1.19, 0.06 2.32), metformin combined 1.06, -1.68 3.80) showed improvements compared placebo. Among these, demonstrated most significant improvement. In terms ranked highest effectiveness, SUCRA score (84.6), followed (SUCRA: 54.1). Low-dose 51.1) also moderate efficacy. some reduction -0.31, -2.82 2.20), although statistical significance limited. Liraglutide exhibited rate withdrawal 1.97, 4.00), while pioglitazone lowest rates 0.07, -0.03 0.17). provides valuable insights into improvement effect on deposition. Metformin emerged effective agent levels, though its function less pronounced. Safety profiles varied, liraglutide associated withdrawals, incidence treatment-related discontinuations. These findings support potential use agents, particularly detemir, therapeutic option further studies are needed confirm their long-term benefits safety.

Язык: Английский

Процитировано

1